Catalysts for the inevitable price POP, page-29

Now this is interesting,
From the same report December 2021-
We know existing pricing to all go to $1500. Below in red has $1250(top end of range) for existing sales.
We have changes to guidelines in green and EST FY2024 to be breakeven.
In Blue expenditure is the same or decreased on Heart & Renal while the ramp up for Lymphoedema domination.



Since April we now know.
Inclusion into guidelines
The cost of new sales to start at $2500. expected for FY2024. now only 2 months away.
Start price for additions to existing contracts $1500 end of FY2023? & into FY2024.
Probability of achieving break even FY2024.

Why is the price target lower now $0.23 with these (improved) knowns as opposed to $0.31 in DEC2021?
Estimate -$40M burn is worth 0.02
Maybe it was Covid euphoric pricing.
Longer term the models would now have to be indicating more juice than previously modelled.
How about 6 years of upgraded prices instead of the last 6 of downgraded prices
Conclusion - If anyone drops any shares on the ground today it would be wise to pick them up and put them in ur pocket.
Trying to understand broker logic.

Regards
Acclivity